North China Pharmaceutical announced that on August 21, 2026, its holding subsidiary Jintan received the “Drug Clinical Trial Approval Notice” for the six-valent recombinant norovirus vaccine approved and issued by the State Drug Administration, and was approved to carry out clinical trials to prevent acute gastroenteritis caused by infection with six types of norovirus genotypes.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.